DXCM — DexCom Share Price
0.000.00%
Last trade - 00:00HealthcareBalancedLarge CapHigh Flyer
- $43.64bn
- $43.02bn
- $2.91bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | 67.7 | ||
| PEG Ratio (f) | 3.74 | ||
| EPS Growth (f) | 22.1% | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 19.24 | ||
| Price to Tang. Book | 20.8 | ||
| Price to Free Cashflow | 87.32 | ||
| Price to Sales | 12.82 | ||
| EV to EBITDA | 63.63 | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | 10.29% | ||
| Return on Equity | 18.42% | ||
| Operating Margin | 14.88% | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | 1,031.6 | 1,476 | 1,926.7 | 2,448.5 | 2,909.8 | 3,592.35 | 4,317.63 | 32.28% |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | +303.66 | -55.38 | +36.31 | +71.48 | +18.95 | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for use by people with diabetes and by healthcare providers. Its Dexcom G6 is a CGM system that can be used as part of an integrated system with other compatible medical devices and electronic interfaces, which may include automated insulin dosing systems, insulin pumps, blood glucose meters or other electronic devices used for diabetes management. Its Dexcom Share remote monitoring system, offered for use with its Dexcom system, uses an application on the patient's mobile device to wirelessly transmit glucose information to the cloud and then to applications on the mobile devices of up to five designated recipients. Its Dexcom Real-Time API enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices. Its other products include Dexcom ONE and Dexcom G7.
Directors
- Kevin Sayer CHM (63)
- Jereme Sylvain CFO (41)
- Sadie Stern CHO (46)
- Jacob Leach EVP (43)
- Donald Abbey EVP (54)
- Andrew Balo EVP (73)
- Paul Flynn EVP (52)
- Patrick Murphy EVP (42)
- Chad Patterson EVP (39)
- Barry Regan EVP (48)
- Sumi Shrishrimal SVP (42)
- Shelly Selvaraj SVP (62)
- Steven Pacelli GMG (49)
- Mark Foletta LED (61)
- Steven Altman IND (59)
- Nicholas Augustinos IND (62)
- Richard Collins IND (64)
- Karen Dahut IND (57)
- Bridgette Heller IND (60)
- Barbara Kahn IND (68)
- Kyle Malady IND (54)
- Jay Skyler IND (74)
- Eric Topol IND (66)
- Last Annual
- December 31st, 2022
- Last Interim
- September 30th, 2023
- Incorporated
- May 13th, 1999
- Public Since
- April 14th, 2005
- No. of Shareholders
- 40
- No. of Employees
- 7,500
- Sector
- Healthcare Equipment & Supplies
- Industry
- Healthcare
- Exchange
- NASDAQ Global Select Market
- Shares in Issue
- 386,373,935
- Address
- 6340 Sequence Dr, SAN DIEGO, 92121-4356
- Web
- https://www.dexcom.com/
- Phone
- +1 8582000200
- Auditors
- Ernst & Young LLP
Upcoming Events for DXCM
Q4 2023 Dexcom Inc Earnings Release
Q1 2024 Dexcom Inc Earnings Release
DexCom Inc Annual Shareholders Meeting
Similar to DXCM
10X Genomics
NASDAQ Global Select Market
Accuray
NASDAQ Global Select Market
Akoya Biosciences
NASDAQ Global Select Market
Align Technology
NASDAQ Global Select Market
Alphatec Holdings
NASDAQ Global Select Market
FAQ
What is the DexCom share price?
As of Today at 18:07 UTC, shares in DexCom are trading at $112.95. This share price information is delayed by 15 minutes.
How has the DexCom share price performed this year?
Shares in DexCom last closed at $112.95 and the price had moved by +0.03% over the past 365 days. In terms of relative price strength the DexCom share price has underperformed the S&P500 Index by -11.67% over the past year.
What are the analyst and broker recommendations for DexCom?
The overall consensus recommendation for DexCom is Buy. You can view the full broker recommendation list by unlocking its StockReport.
What is the DexCom dividend yield?
DexCom does not currently pay a dividend.
Does DexCom pay a dividend?
DexCom does not currently pay a dividend.
When does DexCom next pay dividends?
DexCom does not currently pay a dividend.
How do I buy DexCom shares?
To buy shares in DexCom you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of DexCom?
As of the previous close price of $112.95, shares in DexCom had a market capitalisation of $43.64bn.
Where are DexCom shares listed?
Here are the trading details for DexCom:
- Country of listing: United States
- Exchange: NSQ
- Ticker Symbol: DXCM
What kind of share is DexCom?
Based on an overall assessment of its quality, value and momentum DexCom is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a DexCom share price forecast for 2023?
The analyst consensus target price for shares in DexCom is $124.60. That is 10.31% above the last closing price of $112.95.
Analysts covering DexCom currently have a consensus Earnings Per Share (EPS) forecast of $1.43 for the next financial year.
What is the trend in the DexCom share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like DexCom. Over the past six months, its share price has underperformed the S&P500 Index by -9.44%.
As of the last closing price of $112.95, shares in DexCom were trading +1.38% higher than their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the DexCom PE Ratio?
The DexCom PE ratio based on its reported earnings over the past 12 months is 67.7. The shares last closed at $112.95.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of DexCom?
DexCom's management team is headed by:
- Kevin Sayer - CHM
- Jereme Sylvain - CFO
- Sadie Stern - CHO
- Jacob Leach - EVP
- Donald Abbey - EVP
- Andrew Balo - EVP
- Paul Flynn - EVP
- Patrick Murphy - EVP
- Chad Patterson - EVP
- Barry Regan - EVP
- Sumi Shrishrimal - SVP
- Shelly Selvaraj - SVP
- Steven Pacelli - GMG
- Mark Foletta - LED
- Steven Altman - IND
- Nicholas Augustinos - IND
- Richard Collins - IND
- Karen Dahut - IND
- Bridgette Heller - IND
- Barbara Kahn - IND
- Kyle Malady - IND
- Jay Skyler - IND
- Eric Topol - IND